fig1

Porcupine inhibition: a novel disease-modifier target in arrhythmogenic cardiomyopathy

Figure 1. Canonical Wnt pathway in a cardiomyocyte of a Myh6-Cre-DspW/F mouse model. (1) Upon activation, β-catenin translocates to the nucleus. Its interaction with TCF/LEF activates the expression of a myriad of genes involved in cardiac fibrosis. (2) The inactivation of the canonical Wnt pathway leads β-catenin to proteasomal degradation. (3) Porcupine, a post-translational enzyme localized to the endoplasmic reticulum, palmitoylates Wnt ligands for subsequent transmembrane transport and secretion to the extracellular space. WNT974, a Porcupine inhibitor, blocks this key step thereby suppressing the canonical pathway central to the pathogenesis of arrhythmogenic cardiomyopathy.

The Journal of Cardiovascular Aging

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/